Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
10 Janvier 2025 - 12:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January 2025
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
EXHIBIT INDEX
|
Exhibit No.
|
Description of Exhibit
|
|
99.1
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: January 09,
2025
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit 99.1
Indivior Provides Historical Financials in US GAAP
Slough, UK, and Richmond, VA, January 9, 2025 - Indivior PLC (NASDAQ/LSE: INDV) today has provided historical financial
information in US GAAP and certain reconciliations to IFRS as part
of its transition to a US primary listing.
On May 23, 2024, shareholders overwhelmingly approved moving
Indivior's primary listing to the US. Transitioning to US GAAP
reporting in FY 2025 is the next logical next step in the Group's
transition to the US. US GAAP financial statements are expected to
help facilitate greater US analyst and investor interest and are
required for inclusion in major US equity indices the Group is
targeting.
The historical US GAAP financial information along with
reconciliations to IFRS financials for certain periods can be found
on the Group's website at https://www.indivior.com/en/investors/ifrs-to-us-gaap-conversion.
The Group's most recently published guidance provided to the market
on October 24, 2024, in respect of the year ended December 31,
2024, was issued on an IFRS basis.
With its FY 2024 IFRS results release in February 2025, the Group
will provide FY 2025 guidance items on a U.S. GAAP basis as well as
FY 2024 comparatives on a U.S. GAAP basis. Group results thereafter
will be reported on a U.S. GAAP basis and the Group will provide
its results on SEC Form 10-K and SEC Form 10-Q.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD). Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic
conditions and co-occurring disorders of SUD. Indivior is dedicated
to transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to
expand on its heritage in this category.
Headquartered in the United States in Richmond, VA, Indivior
employs over 1,000 individuals globally and its portfolio of
products is available in over 30 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com
###
Indivior (NASDAQ:INDV)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Indivior (NASDAQ:INDV)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
